NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 05/08/2026
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,676.29 mln
Float83.51 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
23.30
Exceptional upside
Relative Strength
3
/ 100
Severely lagging
Debt / Equity
0.02
Debt-free
ROE
-58.65
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Amylyx Pharmaceuticals is a Cambridge, Massachusetts-based drug development company focused on finding new treatments for rare neurological and hormonal disorders. Its pipeline includes several investigational medicines at various stages of clinical testing, targeting conditions such as ALS, Wolfram syndrome, progressive supranuclear palsy, and post-bariatric hypoglycemia. A key area of focus involves GLP-1 receptor antagonists, a novel class of compounds being studied across multiple rare diseases. Founded in 2013, the company has not yet brought a product to market in the United States.
